Bio-pharma Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, France, China, Japan - Size and Forecast 2024-2028

Published: Dec 2023 Pages: 184 SKU: IRTNTR77011

Biopharmaceuticals Market Size 2024-2028

The global biopharmaceuticals market size is estimated to grow by USD 204.09 billion at a CAGR of 7.98% between 2023 and 2028. Biologics are unique molecular entities that have proven to be more effective than chemical drugs due to the targeted mechanism of action they exert in the body. By providing a targeted action, biologics tend to be more effective and have fewer side effects than small-molecule agents. Hence, the introduction of biological therapy to manage health disorders is driving the growth of the biopharma market at a very rapid pace. Further, the targeted and specific actions offered by biologics have made them acquire a special and highly differentiated place in the biopharmaceuticals market. Physicians prefer biologics as the first line of treatment for various health disorders. This market research and growth also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018-2022, besides analyzing the current market scenario.

What will be the Size of the Biopharmaceuticals Industry during the Market Forecast Period?

To learn more about this report, Download Report Sample

The market is characterized by the utilization of biological sources such as bacteria, yeast, and mammalian cells in biotechnological processes to develop pharmaceutical drugs. These drugs, including small-molecule drugs and those derived from living organisms, target various medical conditions such as autoimmune disorders, hormonal disorders, cardiovascular diseases, and neurological diseases. The market thrives on advancements in genomics and molecular diagnostics, enabling the discovery and development of innovative treatments. Rigorous multi compendial laboratory testing ensures the safety and efficacy of formulations, including active pharmaceutical ingredients and formulation excipients, driving growth in the bio-pharma sector.

Market Segmentation

Technavio has segmented the market into Product, Application, and Geography. The market is at the forefront of combating chronic diseases such as cardiovascular diseases (CVD) and diabetes, which are increasingly prevalent due to factors like aging populations and lifestyle changes. Biological drugs, derived from living organisms, offer innovative treatment options for these health issues, targeting specific disease pathways with high efficacy. In the production of biologic drugs, Multi Compendial Laboratory Testing ensures rigorous quality control and compliance with international standards. Active Pharmaceutical Ingredients (API) play a pivotal role in formulating these drugs, contributing to their therapeutic efficacy and safety. As the demand for effective treatments for chronic diseases continues to rise, pharmaceutical companies are investing heavily in research and development to advance biologic drugs that address the unmet needs of patients worldwide.

By Product

The market share by the monoclonal antibodies segment will be significant during the forecast period. Monoclonal antibodies are high-priced drugs that offer life-saving advantages. Although the sales (in terms of volume) are not as high as that of other pharmaceutical products such as non-steroidal anti-inflammatory drugs and cardiovascular drugs, the revenues generated from individual molecules are high due to the high price of monoclonal antibodies. 

Get a glance at the market contribution of various segments Download PDF Sample

The monoclonal antibodies segment was the largest and was valued at USD 151.68 billion in 2018. Further, the increased incidences of cancer and immunological disorders, where monoclonal antibodies have huge applications, will drive segment growth during the forecast period. Globally, the incidences of cancer and autoimmune disorders, including rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis, are increasing. In line with this, the demand for advanced therapeutics, such as biologics, for treating such chronic and debilitating conditions is increasing, which, in turn, is propelling the demand for monoclonal antibodies that will drive the growth momentum of the monoclonal antibodies segment of the market during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 42% to the growth of the global market during the forecast period. Technavio's analysts have outlined how regional trends and driving forces will influence the market trajectory in the coming forecast period. The United States stands out as a primary driver of growth in the North American biopharmaceutical market, largely due to increased healthcare expenditure dedicated to addressing conditions such as oncology, autoimmune, hormonal, and metabolic disorders. Notably, the prevalence of autoimmune diseases affecting over 50 million Americans annually, as reported by the American Autoimmune Related Diseases Association (AARDA), underscores the significant demand for treatments. Moreover, the presence of numerous regional biopharmaceutical firms and ongoing health research initiatives further boosts the demand for biopharmaceuticals utilized in drug development processes.

Furthermore, prominent pharmaceutical giants like Merck KGaA (Merck), Pfizer Inc. (Pfizer), Amgen Inc. (Amgen), and Bristol Myers Squibb Co. maintain robust footholds in the region. These industry leaders are directing their efforts towards the development of novel drug compounds, thereby stimulating demand for biopharmaceuticals and nurturing the expansion of the North American biopharmaceutical market throughout the projected period.

Buy Full Report Now

Key Market Players 

Enterprises are deploying diverse tactics such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches to bolster their market presence. The report further provides comprehensive analyses of the competitive terrain, detailing insights into 20 key market entities, encompassing:

AbbVie Inc. - The company offers bio pharma products such as Actigall, Actonell, and Acular LS.

  • Amgen Inc.
  • Angelini S.p.a.
  • AspenBio
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Biogen Inc.
  • Bristol Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • Ipsen Pharma
  • Johnson and Johnson
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk AS
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd.
  • Vertex Pharmaceuticals Inc.

The report has conducted both qualitative and quantitative analyses of companies to assist clients in comprehending the broader business landscape, including the strengths and weaknesses of key market participants. Qualitative analysis categorizes companies as pure play, category-focused, industry-focused, and diversified, while quantitative analysis categorizes them as dominant, leading, strong, tentative, and weak.

Market Dynamics and Customer Landscape

The market is experiencing robust growth driven by the increasing prevalence of chronic diseases like cardiovascular disease (CVD) and diabetes, especially among the aging population. Biologic drugs, derived from biological sources such as bacteria, yeast, and mammalian cells, are gaining traction for treating various health issues. Clinical trials are essential for testing the efficacy and safety of these drugs, which are often developed through biotechnological processes. Moreover, advancements in genomics and molecular diagnostics are revolutionizing drug development, particularly for autoimmune disorders, hormonal disorders, and neurological diseases. The market also encompasses the production of small-molecule drugs, formulation excipients, and active pharmaceutical ingredients (APIs), ensuring compliance with compendial standards. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. 

Key Market Drivers

The escalating incidence of health disorders is a prominent driver of market growth. Health disorders, including oncology, metabolic, hormonal, and autoimmune conditions, are witnessing a substantial increase on a global scale. For example, according to the World Health Organization, cancer ranks among the leading causes of death worldwide, claiming nearly 10 million lives in 2020 alone, representing approximately one in six deaths. Furthermore, the prevalence of health disorders is particularly elevated among individuals with conditions such as diabetes mellitus, obesity, high blood pressure, hypertension, and smoking addiction, with the number of affected individuals experiencing significant growth.

Furthermore, this rise in health disorder prevalence is expected to spur demand for corresponding treatments, consequently driving the adoption of biopharmaceuticals and fueling the growth of the biopharmaceutical market during the forecast period.

Significant Market Trends

A growing number of acquisitions by market vendors is an emerging trend shaping market growth. Prominent players in the biopharma market are primarily focusing on various growth strategies such as acquisitions, partnerships, and collaborations to broaden their landscapes and garner large market shares. The market has the presence of international and local players. The prominent players in the market strategically focus on acquisitions to expand their business in the biopharmaceuticals market. Acquisitions help companies to strengthen their product offerings and enhance diversification in supporting the end-users. 

For instance, in January 2021, Angelini Pharma, a subsidiary of Angelini S.p.a., and Arvelle Therapeutics, a biopharmaceutical company, announced that they had reached a definitive merger agreement under which Angelini Pharma would acquire Arvelle Therapeutics. Also, in October 2020, Bayer AG announced the acquisition of Asklepios BioPharmaceutical to broaden its innovation base in cell and gene therapy. Such factors are expected to contribute to the growth of biopharma market growth during the forecast period.

Major Market Challenges

Issues related to the entry of new biopharmaceuticals are a significant challenge hindering the market growth. Several challenges restrict the entry of new biologics into the market. For instance, the strict conditions laid down by regulatory bodies, which do not allow rapid approval of biologics, are a major challenge. Thus, it takes a lot of time and capital investment to develop a new product in the market. Furthermore, to enter the market, new biologics need to ensure higher patient compliance than older biologics.

However, it is difficult for new biopharmaceuticals to find acceptance among patients; the older existing biologics have achieved some level of product differentiation, and they are routinely accepted by physicians and patients. This is one of the major challenges that will negatively affect the growth of the biopharmaceuticals market during the forecast period.

Buy Now Full Report

Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Biopharmaceuticals Market Customer Landscape

Market Analyst Overview

The market addresses the rising challenges of chronic diseases like cardiovascular diseases (CVD) and health issues prevalent among the aging population. It leverages biological drugs derived from living organisms such as bacteria, yeast, and mammalian cells, produced through biotechnological processes. Clinical trials are conducted to test the efficacy of pharmaceutical drugs sourced from biological sources. These drugs, along with small-molecule drugs, undergo compendial and Multi Compendial Laboratory Testing, involving formulation excipients and active pharmaceutical ingredients (API). The market also explores advancements in genomics and molecular diagnostics to address hormonal disorders and neurological diseases through innovative therapeutic approaches.

The market encompasses a wide range of biologic drugs and biosimilars, including anti-TNF products, erythropoietin, and G-CSF, which are vital in treating various conditions like neurological disorders and cancer. Technological advancements have revolutionized cancer treatment, with bio-based drugs and second-generation therapeutics showing promising results in clinical trials. The manufacturing of biopharmaceuticals involves sophisticated equipment and devices, along with analytical methods to ensure quality and efficacy. Patent expirations have led to the emergence of biosimilars and innovative therapies like monoclonal antibodies (mAbs). Regulatory bodies like the FDA oversee the approval and distribution of these drugs, which target biological mechanisms such as cytokines and interferons (IFNs). Cell and gene therapies are also gaining momentum, reshaping the landscape of healthcare delivery worldwide.

Segment Overview

The biopharmaceuticals market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

  • Product Outlook
    • Monoclonal antibodies
    • Recombinant growth factors
    • Vaccine
    • Recombinant hormones
    • Others
    Application Outlook
    • Oncology
    • Autoimmune disorder
    • Metabolic disorder
    • Hormonal disorder
    • Others
  • Region Outlook
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • Rest of World (ROW) 
      • Brazil
      • Argentina 
      • Australia

Biopharmaceuticals Market Scope

Report Coverage

Details

Page number

184

Base year

2023

Historic period

 2018-2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 7.98%

Market Growth 2024-2028

USD 204.09 billion

Market structure

Fragmented

YoY growth 2023-2024(%)

7.35

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 42%

Key countries

US, Germany, France, China, and Japan

Competitive landscape

Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

Key companies profiled

AbbVie Inc., Amgen Inc., Angelini S.p.a., AspenBio, Astellas Pharma Inc., AstraZeneca Plc, Bayer AG, Biogen Inc., Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Ipsen Pharma, Johnson and Johnson, Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Vertex Pharmaceuticals Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period. 

Customization purview

If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the market growth and forecasting between 2024 and 2028
  • Precise estimation of the market size and its contribution of the market in focus to the parent market
  • Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
  • Companies landscape comparing criticality of inputs and factors of differentiation
  • Exclusive Matrix on companies position and classification
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Market growth analysis across North America, Europe, Asia, and Rest of World (ROW)
  • Thorough analysis of the market’s competitive landscape and detailed information about companies
  • Market forecasting of factors that will challenge the growth of biopharma market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Figure 01: Executive Summary – Chart on Market Overview
    • Figure 02: Executive Summary – Data Table on Market Overview
    • Figure 03: Executive Summary – Chart on Global Market Characteristics
    • Figure 04: Executive Summary – Chart on Market by Geography
    • Figure 05: Executive Summary – Chart on Market Segmentation by Product
    • Figure 06: Executive Summary – Chart on Market Segmentation by Application
    • Figure 07: Executive Summary – Chart on Incremental Growth
    • Figure 08: Executive Summary – Data Table on Incremental Growth
    • Figure 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Figure 10: Parent market
    • Figure 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Figure 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Figure 13: Market segments
  • 3.3 Market size 2023
  • 3.4 Market outlook: Forecast for 2023-2028
    • Figure 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
    • Figure 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
    • Figure 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
    • Figure 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

  • 4.1 Global biopharmaceutical market 2018 - 2022
    • Figure 18: Historic Market Size – Data Table on global biopharmaceutical market 2018 - 2022 ($ billion)
  • 4.2 Product Segment Analysis 2018 - 2022
    • Figure 19: Historic Market Size – Product Segment 2018 - 2022 ($ billion)
  • 4.3 Application Segment Analysis 2018 - 2022
    • Figure 20: Historic Market Size – Application Segment 2018 - 2022 ($ billion)
  • 4.4 Geography Segment Analysis 2018 - 2022
    • Figure 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)
  • 4.5 Country Segment Analysis 2018 - 2022
    • Figure 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

  • 5.1 Five forces summary
    • Figure 23: Five forces analysis - Comparison between 2023 and 2028
  • 5.2 Bargaining power of buyers
    • Figure 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
  • 5.3 Bargaining power of suppliers
    • Figure 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
  • 5.4 Threat of new entrants
    • Figure 26: Threat of new entrants – Impact of key factors in 2023 and 2028
  • 5.5 Threat of substitutes
    • Figure 27: Threat of substitutes – Impact of key factors in 2023 and 2028
  • 5.6 Threat of rivalry
    • Figure 28: Threat of rivalry – Impact of key factors in 2023 and 2028
  • 5.7 Market condition
    • Figure 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Product

  • 6.1 Market segments
    • Figure 30: Chart on Product - Market share 2023-2028 (%)
    • Figure 31: Data Table on Product - Market share 2023-2028 (%)
  • 6.2 Comparison by Product
    • Figure 32: Chart on Comparison by Product
    • Figure 33: Data Table on Comparison by Product
  • 6.3 Monoclonal antibodies - Market size and forecast 2023-2028
    • Figure 34: Chart on Monoclonal antibodies - Market size and forecast 2023-2028 ($ billion)
    • Figure 35: Data Table on Monoclonal antibodies - Market size and forecast 2023-2028 ($ billion)
    • Figure 36: Chart on Monoclonal antibodies - Year-over-year growth 2023-2028 (%)
    • Figure 37: Data Table on Monoclonal antibodies - Year-over-year growth 2023-2028 (%)
  • 6.4 Recombinant growth factors - Market size and forecast 2023-2028
    • Figure 38: Chart on Recombinant growth factors - Market size and forecast 2023-2028 ($ billion)
    • Figure 39: Data Table on Recombinant growth factors - Market size and forecast 2023-2028 ($ billion)
    • Figure 40: Chart on Recombinant growth factors - Year-over-year growth 2023-2028 (%)
    • Figure 41: Data Table on Recombinant growth factors - Year-over-year growth 2023-2028 (%)
  • 6.5 Vaccines - Market size and forecast 2023-2028
    • Figure 42: Chart on Vaccines - Market size and forecast 2023-2028 ($ billion)
    • Figure 43: Data Table on Vaccines - Market size and forecast 2023-2028 ($ billion)
    • Figure 44: Chart on Vaccines - Year-over-year growth 2023-2028 (%)
    • Figure 45: Data Table on Vaccines - Year-over-year growth 2023-2028 (%)
  • 6.6 Recombinant hormones - Market size and forecast 2023-2028
    • Figure 46: Chart on Recombinant hormones - Market size and forecast 2023-2028 ($ billion)
    • Figure 47: Data Table on Recombinant hormones - Market size and forecast 2023-2028 ($ billion)
    • Figure 48: Chart on Recombinant hormones - Year-over-year growth 2023-2028 (%)
    • Figure 49: Data Table on Recombinant hormones - Year-over-year growth 2023-2028 (%)
  • 6.7 Others - Market size and forecast 2023-2028
    • Figure 50: Chart on Others - Market size and forecast 2023-2028 ($ billion)
    • Figure 51: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
    • Figure 52: Chart on Others - Year-over-year growth 2023-2028 (%)
    • Figure 53: Data Table on Others - Year-over-year growth 2023-2028 (%)
  • 6.8 Market opportunity by Product
    • Figure 54: Market opportunity by Product ($ billion)
    • Figure 55: Data Table on Market opportunity by Product ($ billion)

7 Market Segmentation by Application

  • 7.1 Market segments
    • Figure 56: Chart on Application - Market share 2023-2028 (%)
    • Figure 57: Data Table on Application - Market share 2023-2028 (%)
  • 7.2 Comparison by Application
    • Figure 58: Chart on Comparison by Application
    • Figure 59: Data Table on Comparison by Application
  • 7.3 Oncology - Market size and forecast 2023-2028
    • Figure 60: Chart on Oncology - Market size and forecast 2023-2028 ($ billion)
    • Figure 61: Data Table on Oncology - Market size and forecast 2023-2028 ($ billion)
    • Figure 62: Chart on Oncology - Year-over-year growth 2023-2028 (%)
    • Figure 63: Data Table on Oncology - Year-over-year growth 2023-2028 (%)
  • 7.4 Autoimmune disorder - Market size and forecast 2023-2028
    • Figure 64: Chart on Autoimmune disorder - Market size and forecast 2023-2028 ($ billion)
    • Figure 65: Data Table on Autoimmune disorder - Market size and forecast 2023-2028 ($ billion)
    • Figure 66: Chart on Autoimmune disorder - Year-over-year growth 2023-2028 (%)
    • Figure 67: Data Table on Autoimmune disorder - Year-over-year growth 2023-2028 (%)
  • 7.5 Metabolic disorder - Market size and forecast 2023-2028
    • Figure 68: Chart on Metabolic disorder - Market size and forecast 2023-2028 ($ billion)
    • Figure 69: Data Table on Metabolic disorder - Market size and forecast 2023-2028 ($ billion)
    • Figure 70: Chart on Metabolic disorder - Year-over-year growth 2023-2028 (%)
    • Figure 71: Data Table on Metabolic disorder - Year-over-year growth 2023-2028 (%)
  • 7.6 Hormonal disorder - Market size and forecast 2023-2028
    • Figure 72: Chart on Hormonal disorder - Market size and forecast 2023-2028 ($ billion)
    • Figure 73: Data Table on Hormonal disorder - Market size and forecast 2023-2028 ($ billion)
    • Figure 74: Chart on Hormonal disorder - Year-over-year growth 2023-2028 (%)
    • Figure 75: Data Table on Hormonal disorder - Year-over-year growth 2023-2028 (%)
  • 7.7 Others - Market size and forecast 2023-2028
    • Figure 76: Chart on Others - Market size and forecast 2023-2028 ($ billion)
    • Figure 77: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
    • Figure 78: Chart on Others - Year-over-year growth 2023-2028 (%)
    • Figure 79: Data Table on Others - Year-over-year growth 2023-2028 (%)
  • 7.8 Market opportunity by Application
    • Figure 80: Market opportunity by Application ($ billion)
    • Figure 81: Data Table on Market opportunity by Application ($ billion)

8 Customer Landscape

  • 8.1 Customer landscape overview
    • Figure 82: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

  • 9.1 Geographic segmentation
    • Figure 83: Chart on Market share by geography 2023-2028 (%)
    • Figure 84: Data Table on Market share by geography 2023-2028 (%)
  • 9.2 Geographic comparison
    • Figure 85: Chart on Geographic comparison
    • Figure 86: Data Table on Geographic comparison
  • 9.3 North America - Market size and forecast 2023-2028
    • Figure 87: Chart on North America - Market size and forecast 2023-2028 ($ billion)
    • Figure 88: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
    • Figure 89: Chart on North America - Year-over-year growth 2023-2028 (%)
    • Figure 90: Data Table on North America - Year-over-year growth 2023-2028 (%)
  • 9.4 Europe - Market size and forecast 2023-2028
    • Figure 91: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
    • Figure 92: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
    • Figure 93: Chart on Europe - Year-over-year growth 2023-2028 (%)
    • Figure 94: Data Table on Europe - Year-over-year growth 2023-2028 (%)
  • 9.5 Asia - Market size and forecast 2023-2028
    • Figure 95: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
    • Figure 96: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
    • Figure 97: Chart on Asia - Year-over-year growth 2023-2028 (%)
    • Figure 98: Data Table on Asia - Year-over-year growth 2023-2028 (%)
  • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
    • Figure 99: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
    • Figure 100: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
    • Figure 101: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
    • Figure 102: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • 9.7 US - Market size and forecast 2023-2028
    • Figure 103: Chart on US - Market size and forecast 2023-2028 ($ billion)
    • Figure 104: Data Table on US - Market size and forecast 2023-2028 ($ billion)
    • Figure 105: Chart on US - Year-over-year growth 2023-2028 (%)
    • Figure 106: Data Table on US - Year-over-year growth 2023-2028 (%)
  • 9.8 China - Market size and forecast 2023-2028
    • Figure 107: Chart on China - Market size and forecast 2023-2028 ($ billion)
    • Figure 108: Data Table on China - Market size and forecast 2023-2028 ($ billion)
    • Figure 109: Chart on China - Year-over-year growth 2023-2028 (%)
    • Figure 110: Data Table on China - Year-over-year growth 2023-2028 (%)
  • 9.9 Germany - Market size and forecast 2023-2028
    • Figure 111: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
    • Figure 112: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
    • Figure 113: Chart on Germany - Year-over-year growth 2023-2028 (%)
    • Figure 114: Data Table on Germany - Year-over-year growth 2023-2028 (%)
  • 9.10 France - Market size and forecast 2023-2028
    • Figure 115: Chart on France - Market size and forecast 2023-2028 ($ billion)
    • Figure 116: Data Table on France - Market size and forecast 2023-2028 ($ billion)
    • Figure 117: Chart on France - Year-over-year growth 2023-2028 (%)
    • Figure 118: Data Table on France - Year-over-year growth 2023-2028 (%)
  • 9.11 Japan - Market size and forecast 2023-2028
    • Figure 119: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
    • Figure 120: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
    • Figure 121: Chart on Japan - Year-over-year growth 2023-2028 (%)
    • Figure 122: Data Table on Japan - Year-over-year growth 2023-2028 (%)
  • 9.12 Market opportunity by geography
    • Figure 123: Market opportunity by geography ($ billion)
    • Figure 124: Data Tables on Market opportunity by geography ($ billion)

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers
  • 10.2 Market challenges
  • 10.3 Impact of drivers and challenges
    • Figure 125: Impact of drivers and challenges in 2023 and 2028
  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview
  • 11.2 Vendor landscape
    • Figure 126: Overview on Criticality of inputs and Factors of differentiation
  • 11.3 Landscape disruption
    • Figure 127: Overview on factors of disruption
  • 11.4 Industry risks
    • Figure 128: Impact of key risks on business

12 Vendor Analysis

  • 12.1 Vendors covered
    • Figure 129: Vendors covered
  • 12.2 Market positioning of vendors
    • Figure 130: Matrix on vendor position and classification
  • 12.3 AbbVie Inc.
    • Figure 131: AbbVie Inc. - Overview
    • Figure 132: AbbVie Inc. - Product / Service
    • Figure 133: AbbVie Inc. - Key news
    • Figure 134: AbbVie Inc. - Key offerings
  • 12.4 Amgen Inc.
    • Figure 135: Amgen Inc. - Overview
    • Figure 136: Amgen Inc. - Product / Service
    • Figure 137: Amgen Inc. - Key offerings
  • 12.5 Astellas Pharma Inc.
    • Figure 138: Astellas Pharma Inc. - Overview
    • Figure 139: Astellas Pharma Inc. - Product / Service
    • Figure 140: Astellas Pharma Inc. - Key news
    • Figure 141: Astellas Pharma Inc. - Key offerings
  • 12.6 AstraZeneca Plc
    • Figure 142: AstraZeneca Plc - Overview
    • Figure 143: AstraZeneca Plc - Product / Service
    • Figure 144: AstraZeneca Plc - Key news
    • Figure 145: AstraZeneca Plc - Key offerings
  • 12.7 Bayer AG
    • Figure 146: Bayer AG - Overview
    • Figure 147: Bayer AG - Business segments
    • Figure 148: Bayer AG - Key news
    • Figure 149: Bayer AG - Key offerings
    • Figure 150: Bayer AG - Segment focus
  • 12.8 Biogen Inc.
    • Figure 151: Biogen Inc. - Overview
    • Figure 152: Biogen Inc. - Product / Service
    • Figure 153: Biogen Inc. - Key offerings
  • 12.9 Bristol Myers Squibb Co.
    • Figure 154: Bristol Myers Squibb Co. - Overview
    • Figure 155: Bristol Myers Squibb Co. - Product / Service
    • Figure 156: Bristol Myers Squibb Co. - Key news
    • Figure 157: Bristol Myers Squibb Co. - Key offerings
  • 12.10 Eli Lilly and Co.
    • Figure 158: Eli Lilly and Co. - Overview
    • Figure 159: Eli Lilly and Co. - Product / Service
    • Figure 160: Eli Lilly and Co. - Key news
    • Figure 161: Eli Lilly and Co. - Key offerings
  • 12.11 F. Hoffmann La Roche Ltd.
    • Figure 162: F. Hoffmann La Roche Ltd. - Overview
    • Figure 163: F. Hoffmann La Roche Ltd. - Business segments
    • Figure 164: F. Hoffmann La Roche Ltd. - Key news
    • Figure 165: F. Hoffmann La Roche Ltd. - Key offerings
    • Figure 166: F. Hoffmann La Roche Ltd. - Segment focus
  • 12.12 Johnson and Johnson
    • Figure 167: Johnson and Johnson - Overview
    • Figure 168: Johnson and Johnson - Business segments
    • Figure 169: Johnson and Johnson - Key news
    • Figure 170: Johnson and Johnson - Key offerings
    • Figure 171: Johnson and Johnson - Segment focus
  • 12.13 Novartis AG
    • Figure 172: Novartis AG - Overview
    • Figure 173: Novartis AG - Business segments
    • Figure 174: Novartis AG - Key offerings
    • Figure 175: Novartis AG - Segment focus
  • 12.14 Novo Nordisk AS
    • Figure 176: Novo Nordisk AS - Overview
    • Figure 177: Novo Nordisk AS - Business segments
    • Figure 178: Novo Nordisk AS - Key offerings
    • Figure 179: Novo Nordisk AS - Segment focus
  • 12.15 Pfizer Inc.
    • Figure 180: Pfizer Inc. - Overview
    • Figure 181: Pfizer Inc. - Product / Service
    • Figure 182: Pfizer Inc. - Key news
    • Figure 183: Pfizer Inc. - Key offerings
  • 12.16 Sanofi SA
    • Figure 184: Sanofi SA - Overview
    • Figure 185: Sanofi SA - Business segments
    • Figure 186: Sanofi SA - Key news
    • Figure 187: Sanofi SA - Key offerings
    • Figure 188: Sanofi SA - Segment focus
  • 12.17 Takeda Pharmaceutical Co. Ltd.
    • Figure 189: Takeda Pharmaceutical Co. Ltd. - Overview
    • Figure 190: Takeda Pharmaceutical Co. Ltd. - Product / Service
    • Figure 191: Takeda Pharmaceutical Co. Ltd. - Key news
    • Figure 192: Takeda Pharmaceutical Co. Ltd. - Key offerings

13 Appendix

  • 13.1 Scope of the report
  • 13.2 Inclusions and exclusions checklist
    • Figure 193: Inclusions checklist
    • Figure 194: Exclusions checklist
  • 13.3 Currency conversion rates for US$
    • Figure 195: Currency conversion rates for US$
  • 13.4 Research methodology
    • Figure 196: Research methodology
    • Figure 197: Validation techniques employed for market sizing
    • Figure 198: Information sources
  • 13.5 List of abbreviations
    • Figure 199: List of abbreviations

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases

DATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts

REPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape

PURCHASE FULL REPORT OF

bio-pharma market market

QUICK BUY

Key Questions Answered

  • What are the key global market and the regional market share?
  • What are the revenue-generating key market segments?
  • What are the key factors driving and challenging this market’s growth?
  • Who are the key market vendors and their growth strategies?
  • What are the latest trends influencing the growth of this market?
  • What are the variables influencing the market growth in the primary regions?
  • What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

  • Off-the-shelf research reports
  • Reports can be tailored to meet the customer's needs
  • Trusted by more than 100 fortune 500 organizations
  • Information about the market's key drivers, trends, and challenges
  • Parent market analysis
  • Every week, 50,000 people visit our subscription platform
  • Detailed vendors report with competitive landscape
  • Covid-19 impact and recovery analysis
  • Data on revenue-generating market segments
  • Details on the market shares of various regions
  • Five-force market analysis